Comparing two ways of taking prostate biopsies to find prostate cancer
Compares two biopsy methods for finding prostate cancer in suspicious areas.
Plain-language title generated from the registry record
Registry title: Cognitive and Fusion Prostatic Biopsy
Key facts
- Where
- Shibīn al Kawm, EgyptSee the site
Where in Egypt
- Menoufia university hospital urology departmentShibīn al Kawm, EgyptNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Menoufia University
- Trial code
- NCT07306741
- Record updated
- 5 January 2026
- Original description
The goal of this study is to compare two different prostate biopsy techniques used to detect prostate cancer. These techniques are cognitive-targeted biopsy (CTB) and magnetic resonance imaging-ultrasound fusion-targeted transrectal biopsy (FTB). Both methods aim to improve the accuracy of prostate cancer detection by targeting suspicious areas identified on prostate imaging. This study will compare how accurately each technique detects prostate cancer, the pathological findings obtained from each biopsy method, and how operator performance may influence the procedure. The information gained from this study may help improve prostate cancer diagnosis and guide future biopsy practices.Read full original descriptionShow less
Cognitive Versus Image Guided Fusion Transrectal Prostatic Biopsy for the Detection of Prostate Cancer
The goal of this study is to compare two different prostate biopsy techniques used to detect prostate cancer. These techniques are cognitive-targeted biopsy (CTB) and magnetic resonance imaging-ultrasound fusion-targeted transrectal biopsy (FTB). Both methods aim to improve the accuracy of prostate cancer detection by targeting suspicious areas identified on prostate imaging. This study will compare how accurately each technique detects prostate cancer, the pathological findings obtained from each biopsy method, and how operator performance may influence the procedure. The information gained from this study may help improve prostate cancer diagnosis and guide future biopsy practices.
Inclusion: Biopsy-naïve patients; Prostate-specific antigen level between 4 and 20 ng/mL; Multiparametric Magnetic Resonance Imaging Prostate Imaging-Reporting and Data System score 4 or 5.
Exclusion: Prior prostate biopsy; Prostate-specific Antigen level outside the specified range; Contraindication to Magnetic Resonance Imaging.